Resistance to Targeted Therapies in Breast Cancer / edited by Jenifer R. Prosperi.

Format:

Book

Contributor:

Prosperi, Jenifer R., editor.

SpringerLink (Online service)

Series:

Biomedical and Life Sciences (Springer-11642)

Resistance to targeted anti-cancer therapeutics 2196-5501 ; 16.

Resistance to Targeted Anti-Cancer Therapeutics, 2196-5501 ; 16

Language:

English

Subjects (All):

Cancer--Research.

Cancer.

Cancer Research.

Local Subjects:

Cancer Research.

Physical Description:

1 online resource (XV, 184 pages) : 12 illustrations.

Edition:

First edition 2017.

Contained In:

Springer eBooks

Place of Publication:

Cham : Springer International Publishing : Imprint: Springer, 2017.

System Details:

text file PDF

Summary:

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (id est, Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (id est, EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy. .

Contents:

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target?

Resistance to HER2-targeted therapy

Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes

EGFR Resistance

Targeting FGFR for the treatment of breast cancer

Targeted Therapies in Breast Cancer

Future paradigm of breast cancer resistance and treatment.

Other Format:

Printed edition:

ISBN:

978-3-319-70142-4

9783319701424

Access Restriction:

Restricted for use by site license.